Molecular Diagnostics Market Trends, Company Share To 2020: Grand View Research, Inc. by Dhanashree

Global Molecular Diagnostics Market to Reach USD 8,020.1 Million by 2020: Grand View Research, Inc

The global market for molecular diagnostics is expected to reach USD 8,020.1 million by 2020, according to a new study by Grand View Research, Inc. Growing demand for personalized medicine and theranostics, and the subsequent introduction of advanced cancer diagnostic technologies are expected to be key factors driving market growth over the next six years. Moreover, the growing global base of geriatric population and chronic diseases such as cancer, coupled with disease triggering lifestyle habits such as smoking and excessive alcohol consumption will positively impact market growth. Molecular diagnostic reagent products dominated the overall market, accounting for over 50% of global revenue in 2013. Reagent market revenue is expected to reach USD 4,739.9 million by 2020, growing at a CAGR of 9.9% from 2014 to 2020. High consumption rates of molecular diagnostic reagents and the growing number of research and development initiatives pertaining to the field of molecular diagnostics are two key drivers of this product segment. The point of care end-use market for molecular diagnostics is expected to be the fastest growing product segment, at an estimated CAGR of 13.3% from 2014 to 2020, on account of factors such as the growing demand for point of care diagnostic procedures as an effective diagnostic tool rendering rapid and accurate results and the introduction of government initiatives such as CLIA (Clinical Laboratory Improvement Amendments) waived tests. View summary of this report @ analysis/molecular-diagnostics-market

http://www.grandviewresearch.com/industry-

Table of Contents Chapter 1. Executive Summary 1.1. Molecular Diagnostics - Industry Summary and Critical Success Factors (CSFs) Chapter 2. Molecular Diagnostics Industry Outlook 2.1. Market Segmentation 2.2. Market Size and Growth Prospects 2.3. Molecular Diagnostics Market Dynamics 2.4. Key Opportunities Prioritized 2.5. Industry Analysis - Porter's 2.6. Molecular Diagnostics - Company Market Share Analysis 2.7. Molecular Diagnostics Market PESTEL Analysis, 2012 Chapter 3. Molecular Diagnostics Product Outlook 3.1. Instruments 3.2. Reagents 3.3. Others Chapter 4. Molecular Diagnostics Technology Outlook 4.1. PCR 4.2. In Situ Hybridization 4.3. Chips and Microarrays 4.4. Mass Spectrometry 4.5. Sequencing 4.6. Others Chapter 5. Molecular Diagnostics Application Outlook 5.1. Oncology 5.2. Pharmacogenomics 5.3. Infectious Disease 5.4. Genetic Testing 5.5. Neurological Disease 5.6. Cardiovascular Disease 5.7. Others Chapter 6. Molecular Diagnostics End-User Outlook 6.1. Point of Care 6.2. Self Test or OTC 6.3. Central Laboratories Chapter 7. Molecular Diagnostics Regional Outlook 7.1. North America 7.2. Europe 7.3. Asia-Pacific 7.4. RoW Chapter 8. Competitive landscape 8.1 Roche Diagnostics 8.1.1 Company Overview 8.1.2 Financial Performance 8.1.3 Product Benchmarking

8.1.4 Strategic Initiatives 8.2 Abbott Laboratories 8.2.1 Company Overview 8.2.2 Financial Performance 8.2.3 Product Benchmarking 8.2.4 Strategic Initiatives 8.3 Siemens Healthcare 8.3.1 Company Overview 8.3.2 Financial Performance 8.3.3 Product Benchmarking 8.3.4 Strategic Initiatives 8.4 Johnson and Johnson 8.4.1 Company Overview 8.4.2 Financial Performance 8.4.3 Product Benchmarking 8.4.4 Strategic Initiatives 8.5 Bio-Rad Laboratories 8.5.1 Company Overview 8.5.2 Financial Performance 8.5.3 Product Benchmarking 8.5.4 Strategic Initiatives 8.6 Beckman Coulter Inc. 8.6.1 Company Overview 8.6.2 Financial Performance 8.6.3 Product Benchmarking 8.6.4 Strategic Initiatives 8.7 Becton Dickinson 8.7.1 Company Overview 8.7.2 Financial Performance 8.7.3 Product Benchmarking 8.7.4 Strategic Initiatives 8.8 bioMerieux 8.8.1 Company Overview 8.8.2 Financial Performance 8.8.3 Product Benchmarking 8.8.4 Strategic Initiatives 8.9 Sysmex 8.9.1 Company Overview 8.9.2 Financial Performance 8.9.3 Product Benchmarking 8.9.4 Strategic Initiatives 8.10 Bayer Healthcare 8.10.1 Company Overview 8.10.2 Financial Performance

8.10.3 Product Benchmarking 8.10.4 Strategic Initiatives 8.11 Alere Inc. 8.11.1 Company Overview 8.11.2 Financial Performance 8.11.3 Product Benchmarking 8.11.4 Strategic Initiatives 8.12 Danaher Corporation 8.12.1 Company Overview 8.12.2 Financial Performance 8.12.3 Product Benchmarking 8.12.4 Strategic Initiatives 8.13 Gen-Probe 8.13.1 Company Overview 8.13.2 Financial Performance 8.13.3 Product Benchmarking 8.13.4 Strategic Initiatives 8.14 Novartis 8.14.1 Company Overview 8.14.2 Financial Performance 8.14.3 Product Benchmarking 8.14.4 Strategic Initiatives 8.15 Cepheid 8.15.1 Company Overview 8.15.2 Financial Performance 8.15.3 Product Benchmarking 8.15.4 Strategic Initiatives 8.16 Qiagen 8.16.1 Company Overview 8.16.2 Financial Performance 8.16.3 Product Benchmarking 8.16.4 Strategic Initiatives 8.17 Leica Biosystems 8.17.1 Company Overview 8.17.2 Financial Performance 8.17.3 Product Benchmarking 8.17.4 Strategic Initiatives 8.18 Dako 8.18.1 Company Overview 8.18.2 Financial Performance 8.18.3 Product Benchmarking 8.18.4 Strategic Initiatives

Chapter 9. Methodology and Scope 9.1. Research Methodology 9.2. Research Scope & Assumption 9.3. List of Data Sources

Browse full report @ http://www.grandviewresearch.com/industry-analysis/moleculardiagnostics-market

List of Tables Molecular Diagnostics – Industry Summary & Critical Success Factors (CSFs) Global Molecular Diagnostics Revenue, 2012 – 2020 (USD million) Global Molecular Diagnostics Market Revenue by Region, (USD million), 2012 - 2020 Global Molecular Diagnostics Market Revenue by Products, (USD million), 2012 – 2020 Global Molecular Diagnostics Market Revenue by Technology, (USD million), 2012 2020 6. Global Molecular Diagnostics Market Revenue by Application, (USD million), 2012 2020 7. Global Molecular Diagnostics Market Revenue by End-Use, (USD million), 2012 - 2020 8. Global Molecular Diagnostic Instruments Demand, 2012 to 2020 (USD million) 9. Global Molecular Diagnostic Instruments Demand, by Region, 2012 to 2020 (USD million) 10. Global Molecular Diagnostic Reagents Demand, 2012 to 2020 (USD million) 11. Global Molecular Diagnostic Reagents Demand, by Region, 2012 to 2020 (USD million) 12. Global Other Molecular Diagnostic Products Demand, 2012 to 2020 (USD million) 13. Global Other Molecular Diagnostic Products Demand, by Region, 2012 to 2020 (USD million) 14. Global PCR based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 15. Global PCR based Molecular Diagnostic Demand, by Region, 2012 to 2020 (USD million) 16. Global In Situ Hybridization based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 17. Global In Situ Hybridization based Molecular Diagnostic Demand, by Region, 2012 to 2020 (USD million) 18. Global Chips and Microarrays based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 19. Global Chips and Microarrays based Molecular Diagnostic Demand, by Region, 2012 to 2020 (USD million) 20. Global Mass Spectrometry based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 21. Global Mass Spectrometry based Molecular Diagnostic Demand, by Region, 2012 to 2020 (USD million) 1. 2. 3. 4. 5.

22. Global Sequencing based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 23. Global Sequencing based Molecular Diagnostic Demand, by Region, 2012 to 2020 (USD million) 24. Global Other Technology based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 25. Global Other Technology based Molecular Diagnostic Demand, by Region, 2012 to 2020 (USD million) 26. Global Molecular Diagnostic Demand for Oncology, 2012 to 2020 (USD million) 27. Global Molecular Diagnostic Demand for Oncology, by Region, 2012 to 2020 (USD million) 28. Global Molecular Diagnostic Demand for Pharmacogenomics, 2012 to 2020 (USD million) 29. Global Molecular Diagnostic Demand for Pharmacogenomics, by Region, 2012 to 2020 (USD million) 30. Global Molecular Diagnostic Demand for Infectious Disease, 2012 to 2020 (USD million) 31. Global Molecular Diagnostic Demand for Infectious Disease, by Region, 2012 to 2020 (USD million) 32. Global Molecular Diagnostic Demand for Genetic Testing, 2012 to 2020 (USD million) 33. Global Molecular Diagnostic Demand for Genetic Testing, by Region, 2012 to 2020 (USD million) 34. Global Molecular Diagnostic Demand for Neurological Disease, 2012 to 2020 (USD million) 35. Global Molecular Diagnostic Demand for Neurological Disease, by Region, 2012 to 2020 (USD million) 36. Global Molecular Diagnostic Demand for Cardiovascular Disease, 2012 to 2020 (USD million) 37. Global Molecular Diagnostic Demand for Cardiovascular Disease, by Region, 2012 to 2020 (USD million) 38. Global Molecular Diagnostic Demand for Other Applications, 2012 to 2020 (USD million) 39. Global Molecular Diagnostic Demand for Other Applications, by Region, 2012 to 2020 (USD million) 40. Global Molecular Diagnostic Demand for Point of Care, 2012 to 2020 (USD million) 41. Global Molecular Diagnostic Demand for Point of Care, by Region, 2012 to 2020 (USD million) 42. Global Molecular Diagnostic Demand for Self Test or OTC, 2012 to 2020 (USD million) 43. Global Molecular Diagnostic Demand for Self Test or OTC, by Region, 2012 to 2020 (USD million) 44. Global Molecular Diagnostic Demand for Central Laboratories, 2012 to 2020 (USD million) 45. Global Molecular Diagnostic Demand for Central Laboratories, by Region, 2012 to 2020 (USD million)

46. North America Molecular Diagnostic Demand, 2012 to 2020 (USD million) 47. North America Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 48. North America Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 49. North America Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 50. North America Molecular Diagnostic Demand, by End-Use, 2012 to 2020 (USD million) 51. Europe Molecular Diagnostic Demand, 2012 to 2020 (USD million) 52. Europe Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 53. Europe Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 54. Europe Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 55. Europe Molecular Diagnostic Demand, by End-Use, 2012 to 2020 (USD million) 56. Asia Pacific Molecular Diagnostic Demand, 2012 to 2020 (USD million) 57. Asia Pacific Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 58. Asia Pacific Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 59. Asia Pacific Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 60. Asia Pacific Molecular Diagnostics Demand, by End-Use, 2012 to 2020 (USD million) 61. RoW Molecular Diagnostic Demand, 2012 to 2020 (USD million) 62. RoW Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 63. RoW Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 64. RoW Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 65. RoW Molecular Diagnostic Demand, by End-Use, 2012 to 2020 (USD million)

For More Information visit analysis/molecular-diagnostics-market

http://www.grandviewresearch.com/industry-

List of Figures 1. Molecular Diagnostics Market Segmentation 2. Global Molecular Diagnostics Market Revenue, 2012 - 2020 3. Molecular Diagnostics Market Dynamics 4. Global population base over the age group of 60 years, 2010 and 2017 (million) 5. Molecular Diagnostics Company Market Share Analysis, 2012 6. Key Opportunities Prioritized 7. Industry Analysis - Porter's 8. Molecular Diagnostics PESTEL Analysis, 2012 9. Global Molecular Diagnostics Market Share, by Product, 2012 & 2020 10. Global Molecular Diagnostic Instruments Demand, 2012 to 2020 (USD million) 11. Global Molecular Diagnostic Reagents Demand, 2012 to 2020 (USD million) 12. Global Other Molecular Diagnostic Products Demand, 2012 to 2020 (USD million) 13. Global Molecular Diagnostics Market Share, by Technology, 2012 & 2020

14. Global PCR based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 15. Global In Situ Hybridization based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 16. Global Chips and Microarrays based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 17. Global Mass Spectrometry based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 18. Global Sequencing based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 19. Global Other Technology based Molecular Diagnostic Demand, 2012 to 2020 (USD million) 20. Global Molecular Diagnostics Market Share, by Application, 2012 & 2020 21. Global Molecular Diagnostic Demand for Oncology, 2012 to 2020 (USD million) 22. Global Molecular Diagnostic Demand for Pharmacogenomics, 2012 to 2020 (USD million) 23. Global Molecular Diagnostic Demand for Infectious Disease, 2012 to 2020 (USD million) 24. Global Molecular Diagnostic Demand for Genetic Testing, 2012 to 2020 (USD million) 25. Global Molecular Diagnostic Demand for Neurological Disease, 2012 to 2020 (USD million) 26. Global Molecular Diagnostic Demand for Cardiovascular Disease, 2012 to 2020 (USD million) 27. Global Molecular Diagnostic Demand for Other Applications, 2012 to 2020 (USD million) 28. Global Molecular Diagnostics Market Share, by End-Use, 2012 & 2020 29. Global Molecular Diagnostic Demand for Point of Care, by Region, 2012 to 2020 (USD million) 30. Global Molecular Diagnostic Demand for Self Test or OTC, by Region, 2012 to 2020 (USD million) 31. Global Molecular Diagnostic Demand for Central Laboratories, 2012 to 2020 (USD million) 32. Global Molecular Diagnostics Market Share, by Region, 2012 & 2020 33. North America Molecular Diagnostic Demand, 2012 to 2020 (USD million) 34. North America Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 35. North America Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 36. North America Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 37. North America Molecular Diagnostic Demand, by End-Use, 2012 to 2020 (USD million) 38. Europe Molecular Diagnostic Demand, 2012 to 2020 (USD million) 39. Europe Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 40. Europe Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 41. Europe Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 42. Europe Molecular Diagnostic Demand, by End-Use, 2012 to 2020 (USD million)

43. Asia Pacific Molecular Diagnostic Demand, 2012 to 2020 (USD million) 44. Asia Pacific Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 45. Asia Pacific Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 46. Asia Pacific Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 47. Asia Pacific Molecular Diagnostics Demand, by End-Use, 2012 to 2020 (USD million) 48. RoW Molecular Diagnostic Demand, 2012 to 2020 (USD million) 49. RoW Molecular Diagnostic Demand, by Product, 2012 to 2020 (USD million) 50. RoW Molecular Diagnostic Demand, by Technology, 2012 to 2020 (USD million) 51. RoW Molecular Diagnostic Demand, by Application, 2012 to 2020 (USD million) 52. RoW Molecular Diagnostic Demand, by End-Use, 2012 to 2020 (USD million)

Further key findings from the study suggest: 

North America dominated the overall market in terms of revenue share in 2013 at 44.6%. The presence of sophisticated healthcare infrastructure, encouraging government initiatives and high patient awareness levels are some of the drivers of this market. In addition, the presence of enhanced R&D activities in the U.S. pertaining to advanced diagnostic technologies attributes to its large market share.



The Asia Pacific molecular diagnostics market is expected to grow at the fastest rate of 12.7% from 2014 to 2020. High unmet medical needs in disease segments such as cancer, diabetes and cardiovascular diseases and the introduction of healthcare reforms in emerging markets such as India and China are some of the factors driving regional market growth.



PCR based molecular diagnostic technology market revenue was estimated to be USD 2,144.3 million in 2013 and is expected to dominate the market over the next six years. Growing demand for genetic testing as an effective tool to develop personalized medicine based products is one of the most significant growth drivers of this market.



Oncology applications dominated the overall market in 2013, accounting for over 30% of total revenue. Unmet medical needs, high global prevalence rates of cancer and the introduction of advanced cancer diagnostic technologies such as companion diagnostics are some of the factors accounting for its large market share.



Some of the key players of this market include Roche Diagnostics, Novartis, Qiagen, bioMerieux, Cepheid, Siemens Healthcare, Hologic, Becton Dickinson and Company, Abbott Laboratories and others.

Request free sample of this Report @ http://www.grandviewresearch.com/industryanalysis/molecular-diagnostics-market/request

For the purpose of this study, Grand View Research has segmented the global molecular diagnostics market on the basis of product and region: Molecular Diagnostics Market Product Outlook • Instruments • Reagents • Others Molecular Diagnostics Market Technology Outlook • PCR • In Situ Hybridization • Chips and Microarrays • Mass Spectrometry • Sequencing • Others Molecular Diagnostics Market Application Outlook • Oncology • Pharmacogenomics • Infectious Disease • Genetic Testing • Neurological Disease • Cardiovascular Disease

• Others Molecular Diagnostics Market End-User Outlook • Point of Care • Self Test or OTC • Hospitals and Clinics Molecular Diagnostics Market Regional Outlook • North America • Europe • Asia Pacific • Rest of the World (RoW)

Browse

All

Reports

this